{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-285325","form_type":"8-K","ticker":"HCWB","cik":"0001828673","company_name":"HCW Biologics Inc.","filed_at":"2025-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.658762+00:00","generated_at":"2026-05-16T18:51:50.095707+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"HCW Biologics doses first patient in Phase 1 trial of HCW9302 for alopecia areata","bullets":["First patient dosed at Ohio State University Wexner Medical Center in multi-center first-in-human Phase 1 trial.","HCW9302 is a subcutaneous IL-2 fusion molecule designed to expand Treg cells, built on the TOBI platform.","Trial plans to enroll up to 30 patients; primary objectives are safety and determination of recommended Phase 2 dose.","Secondary endpoints include disease response and effects on Treg cell proliferation; expansion into other autoimmune and inflammatory conditions is planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-285325","json":"https://secwatch.observer/filing/0001193125-25-285325.json","markdown":"https://secwatch.observer/filing/0001193125-25-285325.md","text":"https://secwatch.observer/filing/0001193125-25-285325.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828673/000119312525285325/0001193125-25-285325-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828673/000119312525285325/hcwb-20251117.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:51:50.095707+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}